AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1951617 — intervention group
Group type: COMPARATOR
Intervention: Most-preferred tasks under purposeful conditions
Number of subjects: 20
Study 1951617 — intervention group
Group type: COMPARATOR
Intervention: Least-preferred tasks under purposeful conditions
Number of subjects: 20
Study 7027827 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5%
Number of subjects: 15
Study 7027827 — intervention group
Group type: EXPERIMENTAL
Intervention: etidocaine 1%
Number of subjects: 15
Study 7027827 — intervention group
Group type: COMPARATOR
Intervention: physiologic saline
Number of subjects: 15
Study 31076476 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergy testing (structured allergy history and skin prick tests)
Number of subjects: 80
Study 31076476 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study 29898030 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Erythropoietin (EPO) - 1 mL of gel containing erythropoietin at a concentration of 4,000 IU mL‐1 applied to the donor site
Number of subjects: 12
Study 29898030 — intervention group
Group type: COMPARATOR
Intervention: Control - 2 mL of gel alone applied to the donor site
Number of subjects: 12
Study 29898030 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Erythropoietin (EPO)
Number of subjects: 12
Study 29898030 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study 27175708 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum elastic bougie (GEB)
Number of subjects: 78
Study 27175708 — intervention group
Group type: EXPERIMENTAL
Intervention: Bougie combined with cricoid displacing (BCD)
Number of subjects: 78
Study 27175708 — intervention group
Group type: COMPARATOR
Intervention: Fiberoptic bronchoscope (FOB)
Number of subjects: 78
Study 24811228 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous arteriovenous exchange (CAVE) technique
Number of subjects: 22
Study 24811228 — intervention group
Group type: COMPARATOR
Intervention: Conventional pull-push (PP) technique
Number of subjects: 22
Study 24811228 — intervention group
Group type: EXPERIMENTAL
Intervention: CAVE technique
Number of subjects: 22
Study 24811228 — intervention group
Group type: COMPARATOR
Intervention: PP technique
Number of subjects: 22
Study 24811228 — intervention group
Group type: EXPERIMENTAL
Intervention: CAVE and PP techniques
Number of subjects: 22
Study 22421389 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbuccal plate fixation
Number of subjects: 261
Study 22421389 — intervention group
Group type: COMPARATOR
Intervention: Intraoral external oblique ridge plate fixation
Number of subjects: 261
Study 22421389 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 261
Study 20955402 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care with Arginine Butyrate administered 5 d/week for 12 weeks
Number of subjects: 27
Study 20955402 — intervention group
Group type: COMPARATOR
Intervention: Standard local care alone (Control Arm)
Number of subjects: 27
Study 20955402 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care with Arginine Butyrate
Number of subjects: 27
Study 18573198 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal fistula plug
Number of subjects: 60
Study 18573198 — intervention group
Group type: COMPARATOR
Intervention: Mucosal advancement flap
Number of subjects: 60
Study 15751606 — intervention group
Group type: COMPARATOR
Intervention: Testosterone treatment
Number of subjects: 151
Study 15751606 — intervention group
Group type: EXPERIMENTAL
Intervention: CDGP
Number of subjects: 151
Study 12494286 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 26
Study 12494286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 9652880 — intervention group
Group type: COMPARATOR
Intervention: Captopril 75 mg/d and placebo (Group A)
Number of subjects: 44
Study 9652880 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 75 mg/d plus losartan 12.5 mg (first dose), then 25 mg/d (Group B)
Number of subjects: 44
Study 8587088 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Malic (200 mg malic acid and 50 mg magnesium, 3 tablets bid)
Number of subjects: 24
Study 8587088 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Malic (up to 6 tablets bid) during open label trial
Number of subjects: 24
Study 8587088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2655501 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.5 mg)
Number of subjects: 30
Study 2655501 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (1 mg)
Number of subjects: 30
Study 2655501 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal methadone (1 mg)
Number of subjects: 30
Study 2655501 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 773068 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglycolic acid (Dexon)
Number of subjects: 326
Study 773068 — intervention group
Group type: COMPARATOR
Intervention: Silk
Number of subjects: 326
Study 29369265 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Clinical Decision Support Systems (CCDSS)
Number of subjects: 50
Study 29369265 — intervention group
Group type: COMPARATOR
Intervention: No further intervention (comparison arm)
Number of subjects: 50
Study 30536185 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sodium hyaluronate (SH) 0.18%
Number of subjects: 30
Study 30536185 — intervention group
Group type: COMPARATOR
Intervention: Control group (DMC)
Number of subjects: 30
Study 28087423 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle cerebral artery pulsatility index at inclusion
Number of subjects: 374
Study 28087423 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle cerebral artery pulsatility index Z-score at inclusion
Number of subjects: 374
Study 28087423 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilicocerebral ratio Z-score at inclusion
Number of subjects: 374
Study 28087423 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestation at delivery
Number of subjects: 374
Study 28087423 — intervention group
Group type: EXPERIMENTAL
Intervention: Birthweight p50 ratio
Number of subjects: 374
Study 25604134 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 25 mg
Number of subjects: 45
Study 25604134 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 50 mg
Number of subjects: 45
Study 25604134 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 100 mg
Number of subjects: 45
Study 25604134 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 45
Study 23247737 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy (LADG)
Number of subjects: 63
Study 23247737 — intervention group
Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 63
Study 21879897 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ITD
Number of subjects: 8718
Study 21879897 — intervention group
Group type: COMPARATOR
Intervention: Sham ITD
Number of subjects: 8718
Study 19164850 — intervention group
Group type: EXPERIMENTAL
Intervention: Coupled bilateral training with a load on the unimpaired hand
Number of subjects: 30
Study 19164850 — intervention group
Group type: EXPERIMENTAL
Intervention: Coupled bilateral training with no load on the unimpaired hand
Number of subjects: 30
Study 19164850 — intervention group
Group type: COMPARATOR
Intervention: Control (no stimulation assistance or load)
Number of subjects: 30
Study 17101557 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D echocardiography
Number of subjects: 34
Study 17101557 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D echocardiography
Number of subjects: 34
Study 17101557 — intervention group
Group type: COMPARATOR
Intervention: ECG (Sokolow-Lyon)
Number of subjects: 34
Study 17101557 — intervention group
Group type: COMPARATOR
Intervention: ECG (Cornell)
Number of subjects: 34
Study 15359398 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincisional wound infiltration of 3 mg/kg ropivacaine (Group I)
Number of subjects: 45
Study 15359398 — intervention group
Group type: EXPERIMENTAL
Intervention: Postincisional wound infiltration of 3 mg/kg ropivacaine (Group II)
Number of subjects: 45
Study 15359398 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group III) - no local anesthetic
Number of subjects: 45
Study 11512129 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-value mean imputation strategies
Number of subjects: 0
Study 11512129 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum likelihood techniques
Number of subjects: 0
Study 11512129 — intervention group
Group type: COMPARATOR
Intervention: Standard complete data formula
Number of subjects: 0
Study 11512129 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum likelihood based analyses
Number of subjects: 0
Study 9709393 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled breathing at 6 breaths/min
Number of subjects: 14
Study 9709393 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled breathing at 10 breaths/min
Number of subjects: 14
Study 9709393 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled breathing at 16 breaths/min
Number of subjects: 14
Study 9709393 — intervention group
Group type: COMPARATOR
Intervention: Chronic metoprolol treatment
Number of subjects: 14
Study 7976801 — intervention group
Group type: EXPERIMENTAL
Intervention: dimethindene maleate (new 'once a day formulation')
Number of subjects: 18
Study 7976801 — intervention group
Group type: COMPARATOR
Intervention: loratadine
Number of subjects: 18
Study 7976801 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 2596365 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestoden triphasic formulation
Number of subjects: 30
Study 2596365 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose combination pill containing desogrestrel
Number of subjects: 30
Study 2596365 — intervention group
Group type: COMPARATOR
Intervention: Gestoden triphasic formulation and Fixed dose combination pill containing desogrestrel
Number of subjects: 30
Study 5440571 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lignocaine (500 mg taken with food)
Number of subjects: 4
Study 5440571 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lignocaine (500 mg taken without food)
Number of subjects: 4
Study 5440571 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lignocaine
Number of subjects: 4
Study 30772830 — intervention group
Group type: EXPERIMENTAL
Intervention: BLS training conducted by emergency physicians
Number of subjects: 460
Study 30772830 — intervention group
Group type: EXPERIMENTAL
Intervention: BLS training conducted by medical students
Number of subjects: 460
Study 30772830 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim retesting
Number of subjects: 460
Study 30772830 — intervention group
Group type: COMPARATOR
Intervention: Control group (no interim retesting)
Number of subjects: 460
Study 28177740 — intervention group
Group type: EXPERIMENTAL
Intervention: 5:40 (24 × 5‐s bouts, 40‐s recovery)
Number of subjects: 9
Study 28177740 — intervention group
Group type: EXPERIMENTAL
Intervention: 15:120 (8 × 15‐s bouts, 120‐s recovery)
Number of subjects: 9
Study 28177740 — intervention group
Group type: EXPERIMENTAL
Intervention: 30:240 (4 × 30‐s bouts, 240‐s recovery)
Number of subjects: 9
Study 28177740 — intervention group
Group type: COMPARATOR
Intervention: CTRL (resting control session)
Number of subjects: 9
Study 26448381 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alfacalcidol therapy for 12 weeks
Number of subjects: 20
Study 26448381 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 non-diabetic HD patients)
Number of subjects: 20
Study 26448381 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (12 healthy subjects)
Number of subjects: 20
Study 24475554 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngoscopy (Group A, n=17)
Number of subjects: 34
Study 24475554 — intervention group
Group type: COMPARATOR
Intervention: Intubating Laryngeal Mask Airway (ILMA) (Group B, n=17)
Number of subjects: 34
Study 21551374 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injections
Number of subjects: 20
Study 21551374 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 20
Study 18819792 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1250 mg/m(2) intravenous (i.v.) on days 1 and 8 of each 21‐day cycle
Number of subjects: 21
Study 16822100 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive Education and Prelinguistic Milieu Teaching (RPMT)
Number of subjects: 36
Study 16822100 — intervention group
Group type: EXPERIMENTAL
Intervention: Picture Exchange Communication System (PECS)
Number of subjects: 36
Study 14518352 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium and magnesium aspartate treatment for three weeks
Number of subjects: 0
Study 14518352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10090430 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (Integrilin) administered to patients undergoing coronary angioplasty; monitored for anti-eptifibatide antibodies at baseline and 30 days after treatment.
Number of subjects: 442
Study 10090430 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (Integrilin) administered to 28 healthy volunteers; 2 infusions 28 days apart, monitored at multiple time points (baseline, 28, 42, 56, 84, and 112 days).
Number of subjects: 442
Study 7672152 — intervention group
Group type: EXPERIMENTAL
Intervention: Single IM injection of 100 mg progestogen (group 1)
Number of subjects: 49
Study 7672152 — intervention group
Group type: COMPARATOR
Intervention: No progestogen (group 2)
Number of subjects: 49
Study 2198069 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal elderly adults
Number of subjects: 40
Study 2198069 — intervention group
Group type: COMPARATOR
Intervention: Normal young adults
Number of subjects: 40
Study 2198069 — intervention group
Group type: COMPARATOR
Intervention: Dysarthric subjects
Number of subjects: 40
Study 7032947 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50, 100, and 200 mg)
Number of subjects: 10
Study 7032947 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (40 mg)
Number of subjects: 10
Study 6585544 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroidal gel
Number of subjects: 18
Study 6585544 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel and capsules (Control)
Number of subjects: 18
Study 6585544 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac (systemically administered nonsteroidal anti-inflammatory drug)
Number of subjects: 18
Study 30894009 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (dual-energy spectral imaging with reduced contrast dose at 0.3 gI/kg)
Number of subjects: 41
Study 30894009 — intervention group
Group type: COMPARATOR
Intervention: Group A (conventional 120kVp scanning protocol with contrast dose at 0.6 gI/kg)
Number of subjects: 41
Study 29973437 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alginate (Ca-Alg) 5%
Number of subjects: 15
Study 29973437 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alginate (Ca-Alg) 8%
Number of subjects: 15
Study 29973437 — intervention group
Group type: COMPARATOR
Intervention: Udon noodles without Ca-Alg
Number of subjects: 15
Study 27488692 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site support (OSS)
Number of subjects: 36
Study 24881806 — intervention group
Group type: COMPARATOR
Intervention: Standard urotherapy treatment alone
Number of subjects: 62
Study 24881806 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard urotherapy + TENS
Number of subjects: 62
Study 24881806 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard urotherapy + TENS (in children without previous treatment)
Number of subjects: 62
Study 24881806 — intervention group
Group type: COMPARATOR
Intervention: Standard urotherapy (in children without previous treatment)
Number of subjects: 62
Study 23043295 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic oil (0.005 mL/L) and ginger oil (0.005 mL/L) mixture
Number of subjects: 0
Study 23043295 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic oil (0.005 or 0.01 mL/L) and ginger oil (0.005 or 0.01 mL/L) mixture
Number of subjects: 0
Study 23043295 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic oil (0.02 mL/L)
Number of subjects: 0
Study 23043295 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger oil (0.01-0.02 mL/L)
Number of subjects: 0
Study 23043295 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic oil or garlic oil-ginger oil mixture
Number of subjects: 0
Study 20528680 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowered patient
Number of subjects: 45
Study 20528680 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer decision support system (CDSS)
Number of subjects: 45
Study 20528680 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 18586224 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-generation strategy (generated condition)
Number of subjects: 38
Study 18586224 — intervention group
Group type: COMPARATOR
Intervention: Provided condition (control)
Number of subjects: 38
Study 17469416 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical sphincteroplasty of the minor papilla
Number of subjects: 0
Study 17469416 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic pancreatic stent placement and/or minor papilla endoscopic papillotomy
Number of subjects: 0
Study 17469416 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic management of symptomatic patients with PD
Number of subjects: 0
Study 17469416 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 0
Study 17469416 — intervention group
Group type: EXPERIMENTAL
Intervention: MRCP
Number of subjects: 0
Study 11811168 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 44
Study 11811168 — intervention group
Group type: COMPARATOR
Intervention: Drink test
Number of subjects: 44
Study 11811168 — intervention group
Group type: COMPARATOR
Intervention: Nepean Dyspepsia Index symptoms
Number of subjects: 44
Study 10089089 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin 12 g/day plus tazobactam 1.5 g/day plus tobramycin 3 mg/kg per day
Number of subjects: 247
Study 10089089 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 3 g/day plus tobramycin 3 mg/kg per day
Number of subjects: 247
Study 7589035 — intervention group
Group type: EXPERIMENTAL
Intervention: RS-86505-007 3 micrograms t.i.d.
Number of subjects: 50
Study 7589035 — intervention group
Group type: EXPERIMENTAL
Intervention: RS-86505-007 6 micrograms t.i.d.
Number of subjects: 50
Study 7589035 — intervention group
Group type: COMPARATOR
Intervention: RS-86505-007
Number of subjects: 50
Study 2405739 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 17201
Study 2405739 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 17201
Study 2405739 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 17201
Study 6930207 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 0
Study 6930207 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous heparin
Number of subjects: 0
Study 31044463 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aripiprazole (3 mg/day)
Number of subjects: 31
Study 31044463 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aripiprazole (up to 12 mg/day)
Number of subjects: 31
Study 31044463 — intervention group
Group type: EXPERIMENTAL
Intervention: Responder group (pHVA levels)
Number of subjects: 31
Study 31044463 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-responder group (pHVA levels)
Number of subjects: 31
Study 28801464 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong protax message
Number of subjects: 5147
Study 28801464 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-sided message
Number of subjects: 5147
Study 28801464 — intervention group
Group type: EXPERIMENTAL
Intervention: Refutation message
Number of subjects: 5147
Study 28801464 — intervention group
Group type: COMPARATOR
Intervention: Control message
Number of subjects: 5147
Study 24961497 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with more category knowledge
Number of subjects: 2
Study 24961497 — intervention group
Group type: COMPARATOR
Intervention: Children with less category knowledge
Number of subjects: 2
Study 24961497 — intervention group
Group type: COMPARATOR
Intervention: Adults
Number of subjects: 2
Study 24096043 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) at low (1 μg/kg/hr) and high (3 μg/kg/hr) doses
Number of subjects: 60
Study 24096043 — intervention group
Group type: COMPARATOR
Intervention: Propofol (PROP) at low (100 μg/kg/m) and high (200 μg/kg/m) doses
Number of subjects: 60
Study 21305525 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg/m² (maximum 20 mg) once weekly for 12 months
Number of subjects: 70
Study 21305525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 19246658 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT(on)
Number of subjects: 7
Study 17535144 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-up
Number of subjects: 52
Study 17535144 — intervention group
Group type: COMPARATOR
Intervention: Cool-down
Number of subjects: 52
Study 15155194 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin 50 mg once daily
Number of subjects: 123
Study 15155194 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin 75 mg once daily
Number of subjects: 123
Study 15155194 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin 100 mg once daily
Number of subjects: 123
Study 11904267 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional nerve block
Number of subjects: 0
Study 11904267 — intervention group
Group type: COMPARATOR
Intervention: Intravenous analgesia
Number of subjects: 0
Study 9988206 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass pollen extract in a hydroglyceric solution
Number of subjects: 20
Study 9988206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7751994 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms HB vaccine (Group A)
Number of subjects: 171
Study 7751994 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms HB vaccine (Group B)
Number of subjects: 171